Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

With the aging of the HIV-infected population in the United States and elsewhere,
neurocognitive dysfunction will likely become an increasingly common problem. Older
individuals could be at increased risk for efavirenz-associated adverse effects due to
impaired metabolism, increased drug-drug interactions, and lower physiologic reserve, but
there are few data on the long-term safety of efavirenz (and other antiretrovirals) in older
individuals with HIV.

The Stanford HIV Aging Cohort (SHAC) is an ideal setting to study potential neurologic
effects of antiretrovirals in aging patients. SHAC is an ongoing longitudinal study
initiated in 2008 to evaluate aging in virologically-suppressed HIV-infected individuals.
The cohort is supported through multiple grants including a grant from the State of
California's HIV Research Program as well as a NIH supplemental grant. As of September 2013,
approximately 150 virologically-suppressed HIV-infected adults have been enrolled. In
addition to enrolling patients with good adherence to ART, the cohort purposefully excludes
subjects with active substance abuse, unstable medical conditions, and psychiatric illnesses
to limit potential confounding the study end points. Recently, an NIH supplemental grant
(AI069556) was received which will expand the SHAC to 300 HIV-infected subjects. The median
age of the subjects in the cohort is in the mid-50's allowing an ample number of older
subjects for our planned studies.

Inclusion Criteria:

- Enrollment into SHAC (Stanford HIV Aging cohort)

- Age over 50 years of age

- Stable antiretroviral therapy containing EFV- or PI-containing ART (but not both) for
at least 6 months

- HIV RNA levels of <200 copies/mL for at least 6 months excluding blips (i.e., a
single measurement between 200-500 copies/mL preceded and followed by measurements of
<200 copies/mL) while on ART.

Exclusion Criteria:

- Completed treatment for any acute systemic infection (other than HIV-1) less than
four weeks before study entry

- Any active brain infection (except for HIV-1), brain neoplasm, or space-occupying
brain lesion.

- Any active psychiatric illness including schizophrenia, severe depression, or severe
bipolar affective disorder that, in the opinion of the investigator, could confound
the analysis of the neuropsychological test results.

- Active drug or alcohol abuse that, in the investigator's opinion, could prevent
compliance with study procedures or confound the analysis of study endpoints.

- Hospitalization within 30 days of study entry

- Receipt of systemic chemotherapy within 30 days of study entry

- Unable to provide informed consent